 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance
July 03, 2012
Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter - Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression
December 1, 2011 / PCR Insider - Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011 / Pharmacogenomics Reporter - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter